Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.754,36 +60,71 (+0,22%) EUR/USD
1,0743 +0,0013 (+0,12%) BTC-EUR
21.276,94 -247,39 (-1,15%) CMC Crypto 200
524,71 -0,43 (-0,08%)
Virbac SA (0NM7.L)
| Chiusura precedente | 349,22 |
| Aperto | 343,00 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 338,50 - 350,00 |
| Intervallo di 52 settimane | 338,50 - 350,00 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
VIRBAC: Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the fourth quarter
KEY FIGURESAnnualRevenue 2022€1,216.1MGrowth at constant exchange rates and scope 1+9.6% of which companion animals +11.9% food-producing animals +6.9%Growth at constant exchange rates+9.6% Overall change+14.3% 1 Growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchang
- GlobeNewswire
Virbac : Declaration of the number of shares and voting rights 12/2022
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20228 458 000Gross total of voting rights : 12 764 896Net total
- GlobeNewswire
VIRBAC : 2023 Outlook
As we continue to execute our 2030 strategic plan, we have made the decision to continue to accelerate in 2023 on two key dimensions : R&D and capital expenditures. In order to maximize the long-term value of our rich R&D portfolio and in-line with our strategic priorities, we intend to boost in 2023 our R&D investment to around 8.5% of our revenues. In parallel, and in order to prepare for the future, to accompany Virbac’s growth and to increase our medium-term productivity we intend to increas
